I did last week see an interesting poster about neuro-immune response after seizures in epilepsy: immune cells leave the spleen after a seizure, and those mice with repeated seizures have activated T4 and T8 cells in their brains. I thought that sounded awfully similar to the stroke story of neuroinflammation and injury (with MultiStem preventing the spleen from shrinking after stroke and providing benefit in stroke recovery in animal models), and was wondering if MultiStem might have another potential indication.
I was responding in the previous post to Expediter's criticism of "finding out they started a trial without a PR" when in fact the trial of MultiStem in AMI has apparently not begun yet (but is scheduled to start this month). NBS had some interesting results recently with a nice dose response to their stem cells in AMI, but the market seemed to have only read the headline results and Adam F.'s description of the events.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM